274 related articles for article (PubMed ID: 30001163)
21. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
22. The odyssey of pacritinib in myelofibrosis.
Venugopal S; Mascarenhas J
Blood Adv; 2022 Aug; 6(16):4905-4913. PubMed ID: 35622972
[TBL] [Abstract][Full Text] [Related]
23. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
Derenzini E; Younes A
Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
[TBL] [Abstract][Full Text] [Related]
24. How many JAK inhibitors in myelofibrosis?
Ferreira BV; Harrison C
Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
[TBL] [Abstract][Full Text] [Related]
25. Clinical potential of pacritinib in the treatment of myelofibrosis.
Duenas-Perez AB; Mead AJ
Ther Adv Hematol; 2015 Aug; 6(4):186-201. PubMed ID: 26288713
[TBL] [Abstract][Full Text] [Related]
26. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
27. Managing patients with myelofibrosis and thrombocytopenia.
Yilmaz M; Verstovsek S
Expert Rev Hematol; 2022 Mar; 15(3):233-241. PubMed ID: 35316110
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
[TBL] [Abstract][Full Text] [Related]
29. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Lancman G; Mascarenhas J
Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
[TBL] [Abstract][Full Text] [Related]
30. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
32. Pacritinib and its use in myelofibrosis associated thrombocytopenia.
Qureshi FA; Zulfi MH; Abbas Z
J Pak Med Assoc; 2023 Jun; 73(6):1353. PubMed ID: 37427653
[No Abstract] [Full Text] [Related]
33. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
[TBL] [Abstract][Full Text] [Related]
34. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
Tremblay D; Hoffman R
Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
[TBL] [Abstract][Full Text] [Related]
35. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Tremblay D; Mesa R; Scott B; Buckley S; Roman-Torres K; Verstovsek S; Mascarenhas J
Blood Adv; 2020 Dec; 4(23):5929-5935. PubMed ID: 33275766
[TBL] [Abstract][Full Text] [Related]
36. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
Gerds AT; Savona MR; Scott BL; Talpaz M; Egyed M; Harrison CN; Yacoub A; Vannucchi A; Mead AJ; Kiladjian JJ; O'Sullivan J; García-Gutiérrez V; Bose P; Rampal RK; Miller CB; Palmer J; Oh ST; Buckley SA; Mould DR; Ito K; Tyavanagimatt S; Smith JA; Roman-Torres K; Devineni S; Craig AR; Mascarenhas JO
Blood Adv; 2020 Nov; 4(22):5825-5835. PubMed ID: 33232476
[TBL] [Abstract][Full Text] [Related]
37. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
38. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
39. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
40. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
